How a rapid-response bird flu vaccine trial is shaping global preparedness
As researchers in the UK launch a pivotal Phase 3 trial of Moderna’s mRNA based vaccine candidate against H5N1 bird flu, volunteer Clare Howard reflects on why she joined a CEPI supported effort to prepare the world for a rapid response to future pandemic flu outbreaks.
